BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res 2011;3:197-205. [PMID: 22163167 DOI: 10.2147/CEOR.S24130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Degroote S, Vandekerckhove L, Vogelaers D, Vanden Bulcke C. Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting. PLoS ONE 2022;17:e0262533. [DOI: 10.1371/journal.pone.0262533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lim ZC, Hoo GS, Ang JH, Teng CB, Ang LW, Lee CC, Leo YS, Law HL, Ng OT, Wong CS. Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS). AIDS Res Ther 2021;18:80. [PMID: 34724931 DOI: 10.1186/s12981-021-00402-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Marcellusi A, Viti R, Russo S, Andreoni M, Antinori A, Mennini FS. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. Clin Drug Investig 2016;36:377-87. [PMID: 26940802 DOI: 10.1007/s40261-016-0382-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Ndou TV, Maputle SM, Risenga PR. HIV-positive patients' perceptions of care received at a selected antiretroviral therapy clinic in Vhembe district, South Africa. Afr J Prim Health Care Fam Med 2016;8:e1-6. [PMID: 27380841 DOI: 10.4102/phcfm.v8i2.926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
5 Sweet DE, Altice FL, Cohen CJ, Vandewalle B. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLoS One 2016;11:e0147821. [PMID: 26808503 DOI: 10.1371/journal.pone.0147821] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
6 Tse WF, Yang W, Huang W. A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes. Clinicoecon Outcomes Res 2015;7:431-9. [PMID: 26316787 DOI: 10.2147/CEOR.S85535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
7 Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag 2014;10:9-15. [PMID: 24379676 DOI: 10.2147/TCRM.S49428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
8 Colombo GL, Di Matteo S, Antinori A, Medaglia M, Murachelli S, Rizzardini G. Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. Clinicoecon Outcomes Res 2013;5:489-96. [PMID: 24124383 DOI: 10.2147/CEOR.S48246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
9 Bernardini C, Maggiolo F. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection. Patient Prefer Adherence 2013;7:531-42. [PMID: 23814462 DOI: 10.2147/PPA.S28797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
10 Porter DP, Guyer B. Clinical Benefits of Single‐tablet Regimens. Successful Strategies for the Discovery of Antiviral Drugs 2013. [DOI: 10.1039/9781849737814-00482] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
11 Colombo GL, Di Matteo S, Maggiolo F. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon Outcomes Res 2013;5:59-68. [PMID: 23430273 DOI: 10.2147/CEOR.S38977] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
12 Beck EJ, Mandalia S, Sangha R, Youle M, Brettle R, Gompels M, Johnson M, Pozniak A, Schwenk A, Taylor S, Walsh J, Wilkins E, Williams I, Gazzard B; NPMS-HHC Steering Group. Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008. PLoS One 2012;7:e47376. [PMID: 23118869 DOI: 10.1371/journal.pone.0047376] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
13 Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL. Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Ther Clin Risk Manag 2012;8:377-84. [PMID: 23028230 DOI: 10.2147/TCRM.S33674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
14 Demberg T, Robert-Guroff M. Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol. 2012;3:250. [PMID: 22912636 DOI: 10.3389/fimmu.2012.00250] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
15 Pimentel-nunes P. Tenofovir como 1a opção terapêutica na hepatite B. GE Jornal Português de Gastrenterologia 2012;19:165-166. [DOI: 10.1016/j.jpg.2012.06.003] [Reference Citation Analysis]